

# Snapshot Pipeline Intelligence — Johnson & Johnson

Run date (UTC): 2026-01-08

Key facts	
Programs extracted	101
Inventory export	reports/jnj/2026-01-08.programs.csv
Phase distribution	Unknown: 101

## Run coverage & provenance

- Run date (UTC): 2026-01-08
- Pipeline source URL: [https://s203.q4cdn.com/636242992/files/doc\\_financials/2025/q3/JNJ-Pipeline-3Q25.pdf](https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf)
- Stored pipeline PDF: `sources/jnj/2026-01-08.pdf`
- Pipeline SHA256: `7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04`
- Programs extracted: 101
- Note: source PDF unchanged; reused prior extracted snapshot to avoid OCR/LLM variability.
- Inventory export (CSV): `reports/jnj/2026-01-08.programs.csv`
- Evidence pack (JSON): `reports/jnj/2026-01-08.evidence.json`

## Pipeline size by phase (snapshot)

- Unknown: 101

## ClinicalTrials.gov coverage

- API base: <https://clinicaltrials.gov/api/v2>
- Programs with matches: 32/101
- Phase mismatches: 0
- Stored CT.gov evidence: `sources/jnj/ctgov/2026-01-08`

## SEC EDGAR coverage

- Filings since: 2025-10-10
- New filings processed: 0
- Filings with extracted events: 0
- Stored EDGAR evidence: `sources/jnj/sec/2026-01-08`

## Programs inventory (excerpt — first 20)

Asset	Indication	Phase	Page
AKEEGA (niraparib/abiraterone)	V11 Metastatic Castration-Sensitive Prostate Cancer		
DARZALEX (daratumumab)	Smoldering Multiple Myeloma		
DARZALEX (daratumumab)	Frontline multiple myeloma transplant ineligible		
IMBRUVICA (ibrutinib)	Frontline Chronic Lymphocytic Leukemia (I + V fixed duration)		

IMBRUVICA (ibrutinib)	Frontline Mantle Cell Lymphoma		
INLEXZO (gemcitabine intravenous) Nodal Positive	Invasive Bladder Cancer		
RYBREVANT (amivantamab)	Frontline Non Small Cell Lung Cancer in combination with chemotherapy		
RYBREVANT (amivantamab)			
Bleximeneb	Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Cytarabine		
CARVYKTI (Ciltacabtagene autoleucel)	Multiple Myeloma TNI		
CARVYKTI (Ciltacabtagene autoleucel)	Multiple Myeloma Transplant Eligible vs ASCT		
ERLEADA (apalutamide)	Localized Prostate Cancer		
ERLEADA (apalutamide)	High Risk Prostate Cancer		
INLEXZO (gemcitabine intravenous) Nodal Positive	Invasive Bladder Cancer BCG-naïve High Risk		
INLEXZO (gemcitabine intravenous) High Systemic	Muscle Invasive Bladder Cancer BGC Experienced		
JNJ-1900 (NBTXR3)	Head and Neck Cancer		
pasritamig	Prostate Cancer		
RYBREVANT (amivantamab)	Colorectal Cancer		
RYBREVANT (amivantamab)	Colorectal Cancer 2L		
TALVEY + TECVAYLI	Relapsed Refractory Multiple Myeloma CD38 exposed		

# Appendix — Pipeline inventory (first 60 rows)

Full inventory in CSV: reports/jnj/2026-01-08.programs.csv

Asset	Indication	Phase	Page
AKEEGA (niraparib/abiraterone)	Metastatic Castration-Sensitive Prostate Cancer		
DARZALEX (daratumumab)	Smoldering Multiple Myeloma		
DARZALEX (daratumumab)	Frontline multiple myeloma transplant ineligible		
IMBRUVICA (ibrutinib)	Frontline Chronic Lymphocytic Leukemia (I + V fixed duration)		
IMBRUVICA (ibrutinib)	Frontline Mantle Cell Lymphoma		
INLEXZO (gemcitabine intravesical)	Invasive Bladder Cancer		
RYBREVANT (amivantamab)	Frontline Non Small Cell Lung Cancer in combination with chemotherapy		
RYBREVANT (amivantamab)			
Bleximenib	Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Blinatumomab		
CARVYKTI (Ciltacabtagene autoleucel)	Potential Multiple Myeloma TNI		
CARVYKTI (Ciltacabtagene autoleucel)	Potential Multiple Myeloma Transplant Eligible vs ASCT		
ERLEADA (apalutamide)	Localized Prostate Cancer		
ERLEADA (apalutamide)	High Risk Prostate Cancer		
INLEXZO (gemcitabine intravesical)	Invasive Bladder Cancer BCG-naïve High Risk		
INLEXZO (gemcitabine intravesical)	High Risk Non Muscle Invasive Bladder Cancer BGC Experienced		
JNJ-1900 (NBTXR3)	Head and Neck Cancer		
pasritamig	Prostate Cancer		
RYBREVANT (amivantamab)	Colorectal Cancer		
RYBREVANT (amivantamab)	Colorectal Cancer 2L		
TALVEY + TECVAYLI	Relapsed Refractory Multiple Myeloma CD38 exposed		
TALVEY (talquetamab)	Relapsed Refractory Multiple Myeloma CD38 exposed		
TALVEY (talquetamab)	Relapsed Refractory Multiple Myeloma A-CD38 Naïve		
TAR-210 (RIS/erdafitinib)	Intravesical Delivery System for Localized Bladder Cancer		
TECVAYLI (teclistamab)	Multiple Myeloma 1-3PLs		
TECVAYLI (teclistamab)	TE NDMM maintenance		
TECVAYLI (teclistamab)	TIE NDMM in combination with DR		
TALVEY + TECVAYLI	TIE NDMM in combination with DR		
TECVAYLI (teclistamab)	Relapsed Refractory Multiple Myeloma CD38 exposed		
Bleximenib	Relapsed Refractory Acute Myeloid Leukemia		
JNJ-0683 (ARX788)	Breast Cancer		
JNJ-1900 (NBTXR3)	Lung Cancer		
TALVEY + TECVAYLI	Relapsed Refractory Multiple Myeloma		
JNJ-0387	Solid Tumors		

JNJ-0631 (ARX305)	Renal Cancer		
JNJ-1493	Hematological Malignancies		
JNJ-2638	Gastrointestinal Cancer		
JNJ-2761	Multiple Myeloma		
JNJ-3413	Lymphoma		
JNJ-4496	Hematological Malignancies		
JNJ-4680	Lung Cancer		
JNJ-4681	Hematological Malignancies		
JNJ-4916	Lung Cancer		
JNJ-5322	Multiple Myeloma		
JNJ-6420	Prostate Cancer		
JNJ-7446	Lung Cancer		
JNJ-8177 (ARX517)	Prostate Cancer		
JNJ-8377	Lymphoma		
JNJ-8543	Hematological Malignancies		
JNJ-9401	Prostate Cancer		
JNJ-9530	Hematological Malignancies		
JNJ-9892	Hematological Malignancies		
JNJ-9968	Hematological Malignancies		
icotrokinra	Psoriasis		
SIMPONI (golimumab)	Pediatric Ulcerative Colitis		
STELARA (ustekinumab)	Pediatric Crohn's Disease		
STELARA (ustekinumab)	Pediatric Ulcerative Colitis		
TREMFYA (guselkumab)	Pediatric Juvenile Psoriatic Arthritis		
TREMFYA (guselkumab)	Pediatric Psoriasis		
TREMFYA (guselkumab)	Psoriatic Arthritis Structural Damage		
TREMFYA (guselkumab)	Ulcerative Colitis Subcutaneous Induction		